No improvement in clinical trial enrollment for adolescents and young adults with cancer at a children's hospital.

abstract：:We describe here the outcomes of reduced-toxicity alternate-donor stem cell transplant (SCT) with posttransplant cyclophosphamide (PTCy) for primary immunodeficiency disorders (PIDs) in eight children (haploidentical-seven and matched unrelated donor-one). The conditioning was with serotherapy (alemtuzumab-3/rabbit-an...

journal_title：Pediatric blood & cancer

authors： Rastogi N,Katewa S,Thakkar D,Kohli S,Nivargi S,Yadav SP

更新日期：2018-01-01 00:00:00

abstract：:Malignant degeneration frequently arises from preexisting plexiform neurofibroma in patients with neurofibromatosis type 1 (NF1). Image guided biopsy for diagnostic purposes, such as with CT guidance, can be technically challenging in these patients, as CT cannot distinguish malignant from benign areas within the same...

journal_title：Pediatric blood & cancer

authors： Koethe Y,Widemann BC,Hajjar F,Wood BJ,Venkatesan AM

更新日期：2013-12-01 00:00:00

abstract：:The objective of this study is to determine the prevalence of adherence to daily medications among children with sickle cell disease (SCD). Prescription records for 12 months were obtained from participants who had insurance in a Medicaid-based single health maintenance organization. Adherence was measured as a ratio ...

journal_title：Pediatric blood & cancer

authors： Patel NG,Lindsey T,Strunk RC,DeBaun MR

更新日期：2010-09-01 00:00:00

abstract：BACKGROUND:We sought to better define the role of hematopoietic cell transplantation (HCT) in first remission (CR1) for high-risk pediatric acute myeloid leukemia (AML). PROCEDURES:Outcomes were compared among patients aged less than 21 years with cytogenetically defined poor-risk AML treated with chemotherapy, matche...

journal_title：Pediatric blood & cancer

authors： Kelly MJ,Horan JT,Alonzo TA,Eapen M,Gerbing RB,He W,Lange BJ,Parsons SK,Woods WG

更新日期：2014-02-01 00:00:00

abstract：BACKGROUND:Chronic myeloid leukemia (CML) is a rare disease in children and represents approximately 2% of all childhood leukemia. This results in difficulty creating large cohorts of patients for pediatric CML research. The Glivec International Patient Assistance Program (GIPAP) is a patient-access program sponsored b...

journal_title：Pediatric blood & cancer

authors： Sadak KT,Fultz K,Mendizabal A,Reaman G,Garcia-Gonzalez P,Levine PH

更新日期：2014-10-01 00:00:00

abstract：BACKGROUND/OBJECTIVES:Sickle cell disease (SCD) is an important, hidden cause of childhood mortality worldwide. It is most prevalent in sub-Saharan Africa where national newborn screening programs remain unavailable and most children in rural areas are never diagnosed. We conducted a study at a rural district hospital ...

journal_title：Pediatric blood & cancer

authors： Eastburg L,Peckham A,Kawira E,Chirangi B,Adler D,Akungo BD,Smart LR,Ambrose EE

更新日期：2020-11-01 00:00:00

abstract：PURPOSE:To assess the safety of delayed high dose intravenous (i.v.) sodium thiosulfate (STS) in a case series of 12 children with malignant brain tumors who were treated with intraarterial (i.a.) carboplatin in conjunction with blood-brain-barrier disruption (BBBD). METHODS:Twelve children ages 17 months-12 years und...

journal_title：Pediatric blood & cancer

authors： Neuwelt EA,Gilmer-Knight K,Lacy C,Nicholson HS,Kraemer DF,Doolittle ND,Hornig GW,Muldoon LL

更新日期：2006-08-01 00:00:00

abstract：BACKGROUND:Survivors of childhood brain tumors are at increased risk for neurocognitive impairments, including deficits in abilities supported by frontal brain regions. Catechol-O-methyltransferase (COMT) metabolizes dopamine in the prefrontal cortex, with the Met allele resulting in greater dopamine availability and b...

journal_title：Pediatric blood & cancer

authors： Howarth RA,Adamson AM,Ashford JM,Merchant TE,Ogg RJ,Schulenberg SE,Ogg S,Li J,Wu S,Xiong X,Conklin HM

更新日期：2014-01-01 00:00:00

abstract：:The provision of tele-practice symptom management is often without the provision of evidence-based guidelines. Under the auspices of the Pediatric Oncology Group of Ontario, a nursing task force was established to appraise the evidence and develop guidelines. Promising new efforts to enhance symptom management through...

journal_title：Pediatric blood & cancer

authors： Tsimicalis A,De Courcy MJ,Di Monte B,Armstrong C,Bambury P,Constantin J,Dagelman B,Eves M,Jansen P,Honeyford L,Stregger D,Pediatric Oncology Group of Ontario.

更新日期：2011-10-01 00:00:00

abstract：BACKGROUND:The goals of this study included: (1) Identification of factors prognostic for event-free survival (EFS) and overall survival (OS), and (2) Definition of risk groups for risk adapted therapy in children with Hodgkin disease (HD). PROCEDURE:From 1991 to 2003, 69 children with newly diagnosed, untreated biops...

journal_title：Pediatric blood & cancer

authors： Oguz A,Karadeniz C,Okur FV,Citak EC,Pinarli FG,Bora H,Akyurek N

更新日期：2005-10-15 00:00:00

abstract：BACKGROUND:Epoetin alfa (EPO, PROCRIT) pharmacokinetics and pharmacodynamics were evaluated in children with malignant solid tumors receiving chemotherapy. PROCEDURE:Children initially received IV EPO 600 IU/kg (max dose 40,000 IU) or placebo once weekly for 16 weeks. Dose was increased to 900 IU/kg (max dose 60,000 I...

journal_title：Pediatric blood & cancer

authors： Freeman BB 3rd,Hinds P,Iacono LC,Razzouk BI,Burghen E,Stewart CF

更新日期：2006-10-15 00:00:00

abstract：:Primary cutaneous lymphomas are rare in children and mostly represented by mycosis fungoides and CD30(+) lymphoproliferative disorders. Most pediatric cutaneous lymphomas have similar clinical/pathological features as their adult counterparts, particularly the T-cell subtypes. With regard to outcome, adult cutaneous m...

journal_title：Pediatric blood & cancer

authors： Ceppi F,Pope E,Ngan B,Abla O

更新日期：2016-11-01 00:00:00

abstract：:Data on prognostic factors in pelvic PNET are minimal. We analyzed patients with pelvic PNET treated between June 2003 and November 2011 for prognostic factors. Forty-eight (13%) of 374 patients with PNET were pelvic PNET with median age 14.5 years (range: 5-33); 31 (65%) had metastases. After median follow-up of 20.4...

journal_title：Pediatric blood & cancer

authors： Biswas B,Agarwala S,Rastogi S,Khan SA,Mohanti BK,Sharma DN,Pathy S,Bakhshi S

更新日期：2013-09-01 00:00:00

abstract：:Although limited data are available about cyclophosphamide disposition in patients with renal insufficiency, nothing has been reported in anephric patients. We characterized cyclophosphamide pharmacokinetics in an anephric child with bilateral Wilms tumor, both on (day 1) and off (day 2) hemodialysis. The median cyclo...

journal_title：Pediatric blood & cancer

authors： McCune JS,Adams D,Homans AC,Guillot A,Iacono L,Stewart CF

更新日期：2006-01-01 00:00:00

abstract：:Social media are powerful means of communication that can also have an important role in the healthcare sector. They are sometimes seen with diffidence in the healthcare setting, partly because they risk blurring professional boundaries. This issue is particularly relevant to relations between caregivers and adolescen...

journal_title：Pediatric blood & cancer

authors： Clerici CA,Quarello P,Bergadano A,Veneroni L,Bertolotti M,Guadagna P,Ricci A,Galdi A,Fagioli F,Ferrari A

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:Primary mediastinal germ cell tumors (GCTs) are rare in children and still represent a challenge for both adult and pediatric oncologists because of their worse outcome compared to their gonadal counterpart. PROCEDURE:Prospectively collected data concerning patients enrolled in the Italian Association of Pe...

journal_title：Pediatric blood & cancer

authors： De Pasquale MD,Crocoli A,Conte M,Indolfi P,D'Angelo P,Boldrini R,Terenziani M,Inserra A

更新日期：2016-05-01 00:00:00

abstract：:Angiotensin converting enzyme (ACE) gene insertion(I)/deletion(D) polymorphism influences the outcome of a number of cardiovascular diseases. ACE I/D polymorphism was investigated by PCR in 207 pediatric cancer patients and 144 controls. ACE I/D distribution of patients and controls was similar. The frequency of the D...

journal_title：Pediatric blood & cancer

authors： Bárdi E,Jenei C,Kiss C

更新日期：2005-08-01 00:00:00

abstract：BACKGROUND:The psychosocial outcomes of young adult survivors of childhood bone tumors are not well known. This study: (a) examined perceived social support (SS) and benefit-finding (BF) with respect to surgical intervention, gender, and age; (b) compared SS and psychological outcomes to normative values; and (c) exami...

journal_title：Pediatric blood & cancer

authors： Teall T,Barrera M,Barr R,Silva M,Greenberg M

更新日期：2013-07-01 00:00:00

abstract：:Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 antibody used for treating patients with CD33+ acute myeloid leukemia (AML). We report three young children (two infants and one toddler) with AML treated with GO 9 mg/m(2). Two received two doses at diagnosis alone with conventional chemotherapy and one received one...

journal_title：Pediatric blood & cancer

authors： Sayar D,Burstein Y,Bielorai B,Toren A,Dvir R

更新日期：2010-07-15 00:00:00

abstract：BACKGROUND:The male excess in childhood cancer incidence is well-established; however, the underlying biologic mechanisms remain unknown. Examining the association between male sex and childhood cancer by single year of age and tumor type may highlight important periods of risk such as variation in growth and hormonal ...

journal_title：Pediatric blood & cancer

authors： Williams LA,Richardson M,Marcotte EL,Poynter JN,Spector LG

更新日期：2019-06-01 00:00:00

abstract：:Risk-adapted, response-based therapies for pediatric Hodgkin lymphoma have resulted in 5-year survival exceeding 90%. Although high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most patients with relapsed or refractory Hodgkin lymphoma, a subset of childr...

journal_title：Pediatric blood & cancer

authors： Harker-Murray PD,Drachtman RA,Hodgson DC,Chauvenet AR,Kelly KM,Cole PD

更新日期：2014-04-01 00:00:00

abstract：:Minimal residual disease (MRD) is an independent predictor of relapse risk in children with leukemia and is widely used for risk-adapted treatment. This article summarizes current evidence supporting the use of MRD, including clinical significance, current international clinical practice, impact statement, and recomme...

journal_title：Pediatric blood & cancer

authors： Athale UH,Gibson PJ,Bradley NM,Malkin DM,Hitzler J,POGO MRD Working Group.

更新日期：2016-06-01 00:00:00

abstract：OBJECTIVE:To examine the level of children's understanding of informed consent in clinical trials and factors that may influence these processes. DESIGN:Twenty nine children who were included in clinical trials for treatment of cancer or HIV, were offered the possibility to complete a semidirective interview, with par...

journal_title：Pediatric blood & cancer

authors： Chappuy H,Doz F,Blanche S,Gentet JC,Tréluyer JM

更新日期：2008-05-01 00:00:00

abstract：BACKGROUND:Chemotherapy-induced nausea and vomiting (CINV) negatively impacts patients' quality of life. The emetogenicity of high-dose methotrexate in children and adolescents with cancer is incompletely characterized. At our institution, a number of patients with acute lymphoblastic leukemia (ALL) have received aprep...

journal_title：Pediatric blood & cancer

authors： Felix-Ukwu F,Reichert K,Bernhardt MB,Schafer ES,Berger A

更新日期：2018-02-01 00:00:00

abstract：INTRODUCTION:The National Heart, Lung, and Blood Institute guidelines for sickle cell disease (SCD) pain crisis management recommend opioids within 60 minutes of emergency department (ED) registration and every 30 minutes thereafter until acute pain is managed. These guidelines are based on expert opinion without publi...

journal_title：Pediatric blood & cancer

authors： Muslu CS,Kopetsky M,Nimmer M,Visotcky A,Fraser R,Brousseau DC

更新日期：2020-09-01 00:00:00

abstract：:Radiation necrosis is a potentially debilitating side effect of therapy necessary to treat pediatric central nervous system tumors. Clinical signs of cerebral radiation necrosis (CRN) are similar to symptoms of disease progression and require close monitoring. The case of an infant diagnosed with a malignant rhabdoid ...

journal_title：Pediatric blood & cancer

authors： L'Hotta AJ,Thomas KM,Milgrom SA,Hemenway MS,Levy JMM

更新日期：2021-01-01 00:00:00

abstract：BACKGROUND:Morphological evaluation of early response to chemotherapy and measurement of minimal residual disease by flow cytometry or PCR are being used for evaluation of prognosis and treatment stratification in children with acute lymphoblastic leukaemia (ALL). PROCEDURE:In a series of 14 consecutive bone marrow in...

journal_title：Pediatric blood & cancer

authors： Helgestad J,Rosthøj S,Johansen P,Varming K,Østergaard E

更新日期：2011-08-01 00:00:00

abstract：BACKGROUND:Patients with cancer who receive intensive chemotherapeutic regimens are subject to profound immunosuppression and are susceptible to an extended array of pathogens. PROCEDURE:The infectious causes of symptomatic gastroenteritis as evidenced by diarrhea +/- fever, vomiting, and abdominal colic in children f...

journal_title：Pediatric blood & cancer

authors： El-Mahallawy HA,El-Din NH,Salah F,El-Arousy M,El-Naga SA

更新日期：2004-04-01 00:00:00

abstract：:Pediatric cancer programs in low-income countries (LIC) can improve outcomes. However, treatment must be tailored to the patient's living conditions and the availability of supportive care. In some cases, a more intense regimen will decrease survival since the increase in death from toxicity may exceed any decrease in...

journal_title：Pediatric blood & cancer

authors： Howard SC,Ortiz R,Baez LF,Cabanas R,Barrantes J,Fu L,Peña A,Samudio A,Vizcaino M,Rodríguez-Galindo C,Barr RD,Conter V,Biondi A,Masera G,MISPHO Consortium Writing Committee.

更新日期：2007-04-01 00:00:00

abstract：BACKGROUND:Self-concept was compared between adult survivors of childhood acute lymphoblastic leukemia (ALL) and sibling controls. Adult survivor subgroups at greatest risk for negative self-concept were identified. PROCEDURE:Survivors (n = 578) aged > or =18 years, treated before age 20 years on Children's Cancer Gro...

journal_title：Pediatric blood & cancer

authors： Seitzman RL,Glover DA,Meadows AT,Mills JL,Nicholson HS,Robison LL,Byrne J,Zeltzer LK

更新日期：2004-03-01 00:00:00